StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold
StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.
皮埃爾斯製藥 (納斯達克:PIRS — 獲得評級) 在周四向客戶和投資者發布的研究報告中,股票分析師將 Stocknews.com 的評級從「買入」評級降至「持有」評級。
Pieris Pharmaceuticals Stock Performance
皮爾斯製藥股票表現
Shares of NASDAQ PIRS opened at $1.40 on Thursday. The company has a 50-day moving average of $1.07 and a 200 day moving average of $1.30. Pieris Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $3.75. The stock has a market cap of $104.17 million, a PE ratio of -2.98 and a beta of 0.95.
納斯達克 PIRS 的股票在周四的 1.40 美元開盤。該公司的移動平均線為 50 天,為 1.07 美元,200 日移動平均線為 1.30 美元。皮爾斯製藥有 12 個月低點 0.85 美元和 12 個月高點 3.75 美元。該股的市值為 10,417 萬美元,私募股票比率為 -2.98,貝塔值為 0.95。
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Pieris Pharmaceuticals had a negative return on equity of 75.31% and a negative net margin of 121.78%. The firm had revenue of $5.37 million during the quarter, compared to analysts' expectations of $4.51 million. On average, sell-side analysts forecast that Pieris Pharmaceuticals will post -0.63 EPS for the current fiscal year.
皮耶斯製藥(NASDAQ:PIRS-獲取評級)上次發布了其季度收益業績於 11 月 2 日(星期三)。該生物技術公司報告了本季度每股收益(0.13 美元),超過了 0.03 美元的共識估計(0.16 美元)。皮爾斯製藥的資產回報率為 75.31%,負淨利潤率為 121.78%。該公司在本季度的收入為 537 萬美元,而分析師的預期為 451 萬美元。平均而言,賣方分析師預測皮爾斯製藥將在本會計年度發布 -0.63 每股盈利。
Institutional Investors Weigh In On Pieris Pharmaceuticals
機構投資者權衡皮爾斯製藥
Pieris Pharmaceuticals Company Profile
皮爾斯製藥公司簡介
(Get Rating)
(取得評分)
Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Pieris 製藥公司是一家臨床階段的生物技術公司,致力於抗膽鹼藥物的發現和開發。其管道包括腫瘤免疫、呼吸系統和貧血等疾病領域。該公司由克勞斯·沙爾珀和阿恩·斯凱拉成立於 2001 年,總部位於馬薩諸塞州波士頓。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 獲取有關皮爾斯製藥(PIRS)的研究報告的免費副本
- 市場節拍週的回顧 — 1/16 — 1/20
- 老自治領是否顯示卡車正在擊中剎車?
- 諾德斯特龍將對減價的恐懼放入零售業
- 埃克森美孚股票:在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收皮埃爾斯製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Pieris 藥品和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。